315 related articles for article (PubMed ID: 18651582)
1. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
Silvestri R
Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
[TBL] [Abstract][Full Text] [Related]
2. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
3. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
4. Beta-secretase as a target for the treatment of Alzheimer's disease.
Citron M
J Neurosci Res; 2002 Nov; 70(3):373-9. PubMed ID: 12391600
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease: from pathology to therapeutic approaches.
Jakob-Roetne R; Jacobsen H
Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
Kreft AF; Martone R; Porte A
J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
[No Abstract] [Full Text] [Related]
7. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
Malamas MS; Barnes K; Hui Y; Johnson M; Lovering F; Condon J; Fobare W; Solvibile W; Turner J; Hu Y; Manas ES; Fan K; Olland A; Chopra R; Bard J; Pangalos MN; Reinhart P; Robichaud AJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2068-73. PubMed ID: 20223661
[TBL] [Abstract][Full Text] [Related]
8. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
9. Progress toward the discovery and development of efficacious BACE inhibitors.
Durham TB; Shepherd TA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
[TBL] [Abstract][Full Text] [Related]
10. The potential for BACE1 inhibitors in the treatment of Alzheimer's disease.
Hussain I
IDrugs; 2004 Jul; 7(7):653-8. PubMed ID: 15243867
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
Probst G; Xu YZ
Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
Asberom T; Bara TA; Clader JW; Greenlee WJ; Guzik HS; Josien HB; Li W; Parker EM; Pissarnitski DA; Song L; Zhang L; Zhao Z
Bioorg Med Chem Lett; 2007 Jan; 17(1):205-7. PubMed ID: 17046254
[TBL] [Abstract][Full Text] [Related]
13. Novel non-peptidic and small-sized BACE1 inhibitors.
Hamada Y; Ohta H; Miyamoto N; Yamaguchi R; Yamani A; Hidaka K; Kimura T; Saito K; Hayashi Y; Ishiura S; Kiso Y
Bioorg Med Chem Lett; 2008 Mar; 18(5):1643-7. PubMed ID: 18261904
[TBL] [Abstract][Full Text] [Related]
14. Gamma-secretase: a complex target for Alzheimer's disease.
Lundkvist J; Näslund J
Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
[TBL] [Abstract][Full Text] [Related]
15. Searching for the most effective screening system to identify cell-active inhibitors of beta-secretase.
Middendorp O; Lüthi U; Hausch F; Barberis A
Biol Chem; 2004 Jun; 385(6):481-5. PubMed ID: 15255179
[TBL] [Abstract][Full Text] [Related]
16. 2,6-Disubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.
Pissarnitski DA; Asberom T; Bara TA; Buevich AV; Clader JW; Greenlee WJ; Guzik HS; Josien HB; Li W; McEwan M; McKittrick BA; Nechuta TL; Parker EM; Sinning L; Smith EM; Song L; Vaccaro HA; Voigt JH; Zhang L; Zhang Q; Zhao Z
Bioorg Med Chem Lett; 2007 Jan; 17(1):57-62. PubMed ID: 17055268
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
18. Simple structure-based approach for predicting the activity of inhibitors of beta-secretase (BACE1) associated with Alzheimer's disease.
Nastase AF; Boyd DB
J Chem Inf Model; 2012 Dec; 52(12):3302-7. PubMed ID: 23198745
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
20. BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides.
Bertini S; Ghilardi E; Asso V; Granchi C; Minutolo F; Pineschi M; Di Bussolo V; Bortolato A; Moro S; Saba A; Macchia M
Bioorg Med Chem; 2010 Nov; 18(22):7991-6. PubMed ID: 20934348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
